Market News How it works Learn FAQ
| RCT 0.0529 -19.36% | DVLT 0.0831 24.03% | CDT 0.0741 -7.38% | STLA 4.785 15.58% | GPUS 0.1903 -10.49% | CHSN 1.57 45.37% | SPCX 144.7761 -2.56% | NVD 3.9599 0.76% | GERN 1.015 -11.74% | EWZ 33.45 -2.48% | BBD 2.76 -5.15% | BRAI 3.62 9.37% | HODO 0.047 -13.28% | NU 12.075 -2.66% | SHFS 0.0892 -22.97% | SOXL 104.321 3.21% | CCC 7.665 -0.45% | SOFI 16.825 2.59% | ONCO 0.57 20.10% | NOK 9.1 2.36% | POM 1.6801 20.87% | WFF 0.0541 -9.98% | BSX 42.8199 -4.97% | SOXS 41.135 -3.20% | INTC 93.9253 0.20% | NVDA 217.03 -0.42% | SKHY 164.065 12.87% | TSLL 11.255 -3.22% | AXG 0.0286 -28.50% | TSLG 5.62 -3.44% | AAL 12.51 -0.79% | RWM 14.33 -0.07% | GCTK 1.985 16.08% | HYG 77.61 0.01% | KORU 13.47 13.58% | KPTI 0.5417 12.85% | HOOD 90.69 -4.09% | WEN 7.0654 15.07% | PACB 3.0477 24.40% | QID 13.835 -0.18% | IREN 27.085 -1.29% | GRAB 2.77 1.84% | CRWV 60.1763 1.02% | TSLA 400.9529 -1.60% | XXII 0.0934 -10.88% | TQQQ 71.29 0.35% | PLUG 1.4013 0.09% | ONDS 6.66 0.15% | VALE 11.455 -3.25% | NFLX 61.84 -1.09%
TCTRACON Pharmaceuticals, Inc. logo

TRACON Pharmaceuticals, Inc. (TCON)

Other OTC · Currency in USD
$0.03 ▲ +0.00 (+0.00%)
As of Jul 16, 4:00 PM ET. Market open.

Summary

Previous Close
$0.03
Open
$0.04
Day's Range
$0.03 – $0.04
52 Week Range
$0.00 – $0.75
Volume
15,047
Avg. Volume
14,433
Market Cap
$109.73K
Beta (5Y Monthly)
1.42
PE Ratio (TTM)
--
EPS (TTM)
-$2.20
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: TRACON Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
17
CEO
Craig R. Jalbert CIRA

TRACON Pharmaceuticals, Inc. functions as a biopharmaceutical enterprise, primarily dedicated to the discovery, development, and eventual market launch of cancer treatments within the United States. Its current product pipeline features several assets in various stages of clinical trials. These include envafolimab (KN035), a PD-L1 single-domain antibody being investigated for the treatment of soft tissue sarcoma, and YH001, an experimental humanized CTLA-4 IgG1 monoclonal antibody targeting a range of cancer indications.

Earnings

DateEst.Actual
Aug 13, 2024-$1.05-$0.94Beat
May 14, 2024-$1.20-$1.33Miss
Mar 5, 2024-$0.60$0.20Beat
Nov 9, 2023-$0.06$5.80Beat
Aug 14, 2023-$6.60-$1.20Beat
May 10, 2023-$5.80-$7.20Miss

Analyst view

Rating: Buy
Buy 88% · Hold 13% · Sell 0%

Get free alerts on TCON and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.